2015
DOI: 10.3324/haematol.2015.133421
|View full text |Cite
|
Sign up to set email alerts
|

Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

2
31
0
3

Year Published

2016
2016
2024
2024

Publication Types

Select...
5
2
1

Relationship

0
8

Authors

Journals

citations
Cited by 33 publications
(36 citation statements)
references
References 37 publications
2
31
0
3
Order By: Relevance
“…This was further supported by the fact that steady-state serum concentrations were quickly reached by cycle two in the highdose cohort, whereas serum concentrations rose steadily over the course of the treatment in the low-dose cohort [64]. Responses were observed more frequently in the high-dose cohort [50] indicating a trend for a dose-response relationship [64].…”
Section: Pharmacologymentioning
confidence: 78%
See 1 more Smart Citation
“…This was further supported by the fact that steady-state serum concentrations were quickly reached by cycle two in the highdose cohort, whereas serum concentrations rose steadily over the course of the treatment in the low-dose cohort [64]. Responses were observed more frequently in the high-dose cohort [50] indicating a trend for a dose-response relationship [64].…”
Section: Pharmacologymentioning
confidence: 78%
“…Responses were observed more frequently in the high-dose cohort [50] indicating a trend for a dose-response relationship [64]. No correlation was seen between to xicity and dose [50,[63][64].…”
Section: Pharmacologymentioning
confidence: 89%
“…Pharmacokinetics for identifying optimal obinutuzumab dosing and schedule were derived from indolent NHL and aggressive NHL patients in the Phase I/II GAUGUIN and Phase IB GAUDI studies 33. Given the differences in mechanism of action, nature of CD20 binding, and signaling pathways activated, the obinutuzumab-dosing schedule could not be extrapolated from rituximab.…”
Section: Obinutuzumabmentioning
confidence: 99%
“…In those patients, the influence of antigenic mass on OBZ exposure was evidenced at lower doses but not at higher doses. 52 PK model-based simulation further demonstrated that a fixed dose of OBZ 1000 mg on days 1, 8, 15, and Figure 2. Mechanics of CD20 recognition by anti-CD20 antibodies, and its relationship with direct cytotoxicity.…”
Section: Pharmacokinetics and Pharmacodynamicsmentioning
confidence: 99%
“…51 In OBZ PK studies including CLL and NHL patients, the influence of BSA/weight on exposure remains controversial. 52,53 Using higher doses at the beginning of treatment in order to quickly improve exposure and saturate targets was also suggested. 50,54,55 Indeed, higher doses infused at days 1 and 8 (1600 mg) followed by infusions of 800 mg improved exposure and overall response rates (ORRs) in NHL, compared with lower doses (400 mg).…”
Section: Pharmacokinetics and Pharmacodynamicsmentioning
confidence: 99%